Background
Analytical treatment interruption (ATI) is critical to investigate immunologic post-treatment control (PTC) in people living with HIV (PWH). In the eCLEAR study, newly diagnosed PWH were randomized to start ART only, ART+the broadly neutralizing antibody (bnAb) 3BNC117, ART+romidepsin (a latency reversal drug), or ART+3BNC117+romidepsin. One year later, 20 PWH underwent ATI. Individuals whose viruses were sensitive to 3BNC117 (defined IC90<1.5 µg/mL) at initial treatment experienced delayed or no rebound [Gunst et al. Nat Med (2022)]. However, it remains unclear whether bnAb sensitivity continuously relates to host-immune responses and subsequent viral rebound kinetics.
Methods
We previously trained an HIV viral dynamics model inclusive of bnAb kinetics to viral loads from the antibody mediated prevention (AMP) trials [Reeves et al. Nat Comm (2023)]. To assess the hypothesis that bnAb administration can enhance host-specific anti-HIV immunity (e.g. vaccinal effect), we now model how bnAb sensitivity influences the death of infected cells and the recruitment of adaptive immunity. To validate the model, we demonstrated recapitulation of primary infection viral loads (N=46 individuals from the RV217 study), which differs from rebound as immunity is not already developed. Then, we fitted the model to rebound viral loads from the eCLEAR study (N=20) as well as 24 individuals (9 with PTC) collected from ACTG studies [Sharaf et al. JCI (2018)]. We used population nonlinear mixed effects to estimate parameters (Fig 1A) including the underlying day that rebound began (before detection), the death rate of infected cells, and the initial size as well as growth rate of an adaptive immune compartment. We tested whether parameters continuously associated with pre-treatment bnAb IC80s.
Results
By varying model parameters, we matched viral loads from primary infection, typical ATI rebound and PTC. We found a continuous dose-response effect whereby increased pre-ART bnAb sensitivity was associated with enhanced rates of infected cell death and adaptive immune recruitment during ATI (Fig 1B). Both rates approximately doubled from least to most sensitive IC80s.
Conclusions
These results suggest that sensitivity of an individual’s HIV virus to a potent bnAb continuously enhances both infected cell killing and immune recruitment to help control viremia after ATI. Our modeling provides a generalized framework to analyze the multifactorial relationship between therapy and host immune responses to HIV.
Table or Figure
